The FDA, on Aug 22, approved/authorized the updated mRNA-based COVID-19 vaccines of Pfizer PFE/BioNTech BNTX and Moderna MRNA that target the KP.2 strain of the virus.

Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

KEY TAKEAWAYS Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Drug developers Moderna Thursday filed for clearance from the US Food and Drug Administration (FDA) to extend the use of their COVID-19 vaccine to children aged 6 months to 5 years, it was announced.

Moderna has asked the FDA for emergency use authorisation for ... while Moderna is going for a broad approval in all adults. In a statement, Moderna said the request to include all over-18s ...

Moderna Inc's coronavirus vaccine on Friday became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering ...

Moderna is most well known for its Covid-19 vaccine, which is called Spikevax. The most recent version of Spikevax was approved by the U.S. Food and Drug Administration in August ahead of the fall ...

These mutations negatively affected the effectiveness of the original vaccines and prompted drug ... Moderna and Pfizer-BioNTech converted their vaccines from monovalent to bivalent. Approved ...